Compare GCO & DRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GCO | DRTS |
|---|---|---|
| Founded | 1924 | 2015 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 321.1M | 300.2M |
| IPO Year | N/A | N/A |
| Metric | GCO | DRTS |
|---|---|---|
| Price | $23.89 | $4.90 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | ★ $31.33 | $8.00 |
| AVG Volume (30 Days) | ★ 171.4K | 140.5K |
| Earning Date | 12-04-2025 | 11-20-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.00 | N/A |
| Revenue | ★ $2,382,104,000.00 | N/A |
| Revenue This Year | $4.60 | N/A |
| Revenue Next Year | $2.14 | N/A |
| P/E Ratio | $6,453.36 | ★ N/A |
| Revenue Growth | ★ 2.76 | N/A |
| 52 Week Low | $16.19 | $2.30 |
| 52 Week High | $44.80 | $5.07 |
| Indicator | GCO | DRTS |
|---|---|---|
| Relative Strength Index (RSI) | 31.66 | 68.59 |
| Support Level | $22.63 | $3.84 |
| Resistance Level | $24.38 | $5.07 |
| Average True Range (ATR) | 1.80 | 0.34 |
| MACD | -1.22 | 0.13 |
| Stochastic Oscillator | 13.18 | 90.24 |
Genesco Inc. sells footwear, headwear, sports apparel, and accessories through four main segments. The Journeys Group generates the highest revenue, encompassing the Journeys, Journeys Kidz, and Little Burgundy brands, along with e-commerce and catalog sales. The Schuh Group targets teenagers and young adults aged 16 to 24, focusing on casual and athletic footwear. The Johnston & Murphy Group operates retail shops and factory stores across the United States. Finally, the Genesco Brands Group designs and sources licensed footwear for brands like Levi's, Dockers, and G.H. Bass.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company derives maximum revenue from Israel.